RxDoctor Payments Data

Marlene Taylor

Physician Assistant · New York, NYNPI 1467678920

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $73,043 of the $109,360 with a category attached, or 66.8%. Gilead accounts for 67.7% of it on its own, with 10 other manufacturers making up the rest. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,360in general payments, 2019–2025

Across 322 payments — averaging $339.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$74K
  • Viiv Healthcare Company$34K
  • Janssen Products, LP$816
  • Exact Sciences$163
  • Merck$145
  • Johnson & Johnson$117
  • plus $260 from 5 others

What the payments were for

  • Consulting fees$6,8506%
  • Speaking & faculty fees$73,04367%
  • Travel & lodging$19,74118%
  • Food & beverage$9,5719%
  • Education$1560%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,360 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala111$418,344
GenvoyaElviteg/Cob/Emtri/Tenof Alafen62$238,321
DovatoDolutegravir Sodium/Lamivudine56$159,175
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$116,790
CabenuvaCabotegravir/Rilpivirine16$104,964
TivicayDolutegravir Sodium18$37,788
OzempicSemaglutide37$37,229
JardianceEmpagliflozin18$16,056
JanuviaSitagliptin Phosphate21$12,095
EntrestoSacubitril/Valsartan16$10,606
EliquisApixaban11$9,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,196
Incruse ElliptaUmeclidinium Bromide19$5,734
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,348
FarxigaDapagliflozin Propanediol11$4,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$74,041$656,665173 claims
Viiv Healthcare CompanyDovato, Cabenuva, Tivicay$33,818$301,92690 claims
Janssen Products, LPSymtuza$816$116,79025 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$56$16,99543 claims
MerckJanuvia$145$12,09521 claims
AstraZenecaFarxiga$36$4,99911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →